We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.


BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel.Study met key secondary endpoints showing statistically significant improvement for the combination against docetaxel alone in ORR, PFS,...

read more


No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.